Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay
|
Homo sapiens
|
1.7
nM
|
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction of total cellular NAD(P) level
|
Homo sapiens
|
0.5
nM
|
|
Cytotoxicity against human HT1080 cells after 6 days by SRB assay
|
Homo sapiens
|
160.0
nM
|
|
Antitumor activity against human MCF7 cells at 10 uM after 6 days by SRB assay
|
Homo sapiens
|
680.0
nM
|
|
Cytotoxicity against human A549 cells after 6 days by SRB assay
|
Homo sapiens
|
160.0
nM
|
|
Cytotoxicity against human HCT116 cells after 6 days by SRB assay
|
Homo sapiens
|
160.0
nM
|
|
Cytotoxicity against human SNU638 cells after 6 days by SRB assay
|
Homo sapiens
|
160.0
nM
|
|
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
|
Homo sapiens
|
1.0
nM
|
|
Inhibition of Nampt (unknown origin) using NAM/PRPP as substrate preincubated for 15 mins measured after 30 mins
|
Homo sapiens
|
3.0
nM
|
|
Cytotoxicity against human K562 cells after 96 hrs by MTT assay
|
Homo sapiens
|
7.2
nM
|
|
Noncompetitive inhibition of NAMPT (unknown origin)
|
Homo sapiens
|
0.3
nM
|
|
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis
|
Homo sapiens
|
1.0
nM
|
|
Inhibition of C-terminal His-tagged NAMPT (unknown origin) expressed in Escherichia coli BL21 using nicotinamide as substrate preincubated for 15 mins before substrate addition measured after 30 mins by mass spectrometry-based assay
|
Homo sapiens
|
3.0
nM
|
|
Cytotoxicity against human SKOV3 cells by clonogenic assay
|
Homo sapiens
|
211.0
nM
|
|
Cytotoxicity against human NYH cells by clonogenic assay
|
Homo sapiens
|
1.5
nM
|
|
Cytotoxicity against human PC3 cells by clonogenic assay
|
Homo sapiens
|
3.8
nM
|
|
Cytotoxicity against human MCF7 cells by clonogenic assay
|
Homo sapiens
|
8.4
nM
|
|
Cytotoxicity against human A431 cells by clonogenic assay
|
Homo sapiens
|
6.1
nM
|
|
Cytotoxicity against human A2780 cells by clonogenic assay
|
Homo sapiens
|
5.7
nM
|
|
Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis
|
Homo sapiens
|
2.2
nM
|
|
Cytotoxicity against APO866-resistant human HCT116 cells assessed as growth inhibition after 72 hrs by WST-1 assay
|
Homo sapiens
|
946.0
nM
|
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by WST-1 assay
|
Homo sapiens
|
10.9
nM
|
|
Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay
|
Homo sapiens
|
7.4
nM
|
|
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay
|
Homo sapiens
|
1.6
nM
|
|
Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay
|
Homo sapiens
|
1.0
nM
|
|
Inhibition of C-terminal His-tagged human full-length NAMPT expressed in Escherichia coli Rosetta DE3 using nicotinamide as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins in presence of PRPP
|
Homo sapiens
|
3.0
nM
|
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
Homo sapiens
|
3.2
nM
|
|
Inhibition of recombinant mouse NAMPT expressed in bacteria assessed as reduction in NADH formation using [14C]NAM as substrate measured for 1 hr by coupled enzymatic assay
|
Mus musculus
|
61.0
nM
|
|
Inhibition of NAMPT in human SH-SY5Y cells assessed as NAD depletion incubated for 16 hrs
|
Homo sapiens
|
0.0301
nM
|
|
Inhibition of human full length C-terminal His6-tagged NAMPT expressed in Escherichia coli Rosetta (DE3) cells using nicotinamide as substrate incubated for 15 mins prior to substrate addition measured after 30 mins in presence of PRPP
|
Homo sapiens
|
3.0
nM
|
|
Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay
|
Homo sapiens
|
1.0
nM
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis
|
Homo sapiens
|
540.0
nM
|
|
Inhibition of recombinant mouse NAMPT expressed in bacterial expression system using nicotinamide as substrate after 1 hr by fluorescence based NMNAT-3 enzyme coupled assay
|
Mus musculus
|
4.9
nM
|
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 56 hrs by MTT assay
|
Homo sapiens
|
3.4
nM
|
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability
|
Homo sapiens
|
4.2
nM
|
|
Inhibition of human recombinant NAMPT using NAM as substrate preincubated for 5 mins followed by substrate addition measured after 15 mins by fluorescence assay
|
Homo sapiens
|
9.0
nM
|
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
Homo sapiens
|
890.0
nM
|
|
Inhibition of C-terminal His-tagged human recombinant NAMPT using FK866 or isoindoline urea-based Oregon green (488) probe incubated for 3 hrs by TR-FRET assay
|
Homo sapiens
|
3.0
nM
|
|
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay
|
Homo sapiens
|
5.7
nM
|
|
Inhibition of NAMPT (unknown origin) using NAM as substrate incubated for 5 mins followed by substrate addition measured after 15 mins by fluorometric method
|
Homo sapiens
|
9.0
nM
|
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
Homo sapiens
|
890.0
nM
|
|
Inhibition of human full length C-terminal flag/His-tagged NAMPT (1 to 491 residues) expressed in HEK293-6E cells by TR-FRET assay
|
Homo sapiens
|
5.0
nM
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
51.39
%
|
|
Displacement of fluorescent labelled OG488 from human full length FLAG-tagged NAMPT (1 to 491 residues) expressed in HEK293-6E cells in absence of PRPP by TR-FRET assay
|
Homo sapiens
|
6.0
nM
|
|
Displacement of fluorescent labelled OG488 from human full length FLAG-tagged NAMPT (1 to 491 residues) expressed in HEK293-6E cells in presence of PRPP by TR-FRET assay
|
Homo sapiens
|
0.2
nM
|
|
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability by Celltiter-Glo assay
|
Homo sapiens
|
6.0
nM
|
|
Cytotoxicity against human SH-SY5Y cells measured after 48 hrs by MTT assay
|
Homo sapiens
|
2.5
nM
|
|
Inhibition of recombinant mouse wild-type NAMPT expressed in bacterial expression system using PRPP as substrate in presence of mouse NMNAT-3 measured for 1 hr by fluorescence assay
|
Mus musculus
|
2.7
nM
|
|
Inhibition of recombinant NAMPT (unknown origin) using NAM and PRPP as substrates incubated for 60 mins in presence of NMNAT1 measured at 5 mins interval for 30 mins by WST1 assay
|
Homo sapiens
|
6.8
nM
|
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay
|
Homo sapiens
|
0.96
nM
|
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay
|
Homo sapiens
|
0.41
nM
|
|
Antiproliferative activity against human DU145 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay
|
Homo sapiens
|
5.12
nM
|
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay
|
Homo sapiens
|
3.75
nM
|
|
Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutation assessed as inhibition of cell growth after 72 hrs by CCK-8 assay
|
Homo sapiens
|
4.76
nM
|
|
Antiproliferative activity against human HuH7 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay
|
Homo sapiens
|
1.05
nM
|
|
Inhibition of recombinant NAMPT (unknown origin) using nicotinamide as substrate measured every 5 mins for 30 mins in presence of recombinant NMNAT1
|
Homo sapiens
|
32.0
nM
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
10.05
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
17.05
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.19
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.59
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.19
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.59
%
|
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
Homo sapiens
|
18.72
nM
|
|
Inhibition of recombinant NAMPT (unknown origin) using nicotinamide and pyrophosphate as substrate incubated for 60 mins and measured for 30 mins at 5 mins interval by colorimetric assay
|
Homo sapiens
|
20.7
nM
|
|